Compare Eaton Corporation plc (ETN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Merck & Co., Inc. — how do they compare? Eaton Corporation plc trades at $398.04 (market cap $160.31B), while Merck & Co., Inc. trades at $127.82 (market cap $305.29B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| ETN | MRK | |
|---|---|---|
Market Cap | $160.31B | $305.29B |
Sector | Technology | Health |
52-Week High | $435.78 | $129.52 |
52-Week Low | $315.82 | $77.60 |
Enterprise Value | $181.40B | $348.71B |
Dividend Yield | 1.07% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $395.5, down 4.82% over 24 hours, but remains near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $392. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding the $2.73 estimate. Revenue for 2025 reached $27.45 billion, with a net income margin of 13.99%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $449.50 and 64.1% of analysts rating it a Buy.
The outlook for ETN is favorable, driven by strong demand in data center power infrastructure and recent strategic acquisitions. However, risks include elevated valuation multiples like a P/E of 40.4 and potential macroeconomic pressures on industrial spending. The stock offers upside to the consensus target but requires monitoring of execution on growth initiatives and competitive dynamics in the power management sector.
MRK trades at $127.65, up 5.67% today, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting the uptrend. Fundamentally, the company reported robust 2025 results with revenue of $65.01B and net income of $18.25B, and recently announced the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline. Analyst consensus is strongly positive with a $137.30 price target.
The outlook for MRK is favorable, driven by earnings beats, strategic acquisitions, and solid profitability. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. The stock presents a growth opportunity with upside to the consensus target, though investors should monitor integration of new acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
